Published in Ann Neurol on September 01, 2001
Peripheral neuropathy. BMJ (2002) 1.56
Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol (2011) 1.38
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry (2015) 1.29
A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med (2009) 0.99
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry (2005) 0.98
Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol (2008) 0.91
Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord (2009) 0.88
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins. Biologics (2010) 0.86
Chronic Inflammatory Demyelinating Polyradiculoneuropathy. J Clin Immunol (2010) 0.85
Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention. Acta Neuropathol (2015) 0.83
Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin. J Neurol Neurosurg Psychiatry (2005) 0.82
Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry (2006) 0.81
Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach. Muscle Nerve (2015) 0.80
CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy. Clin Exp Immunol (2014) 0.80
Serum IgG antibodies to P0 dimer and 35 kDa P0 related protein in neuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry (2003) 0.79
Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat (2002) 0.79
Animal models of autoimmune neuropathy. ILAR J (2014) 0.76
Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat (2002) 0.76
Chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 0.75
Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP. BMC Neurol (2017) 0.75
Reply: biomarkers of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain (2014) 0.75
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. Medicine (Baltimore) (2016) 0.75
Chronic inflammatory demyelinating polyradiculoneuropathy with ataxia. J R Soc Med (2004) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 3.67
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol (2000) 2.07
Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain (1987) 1.98
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86
MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology (1999) 1.80
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Improved diffusion-weighted single-shot echo-planar imaging (EPI) in stroke using sensitivity encoding (SENSE). Magn Reson Med (2001) 1.69
Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60
Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med (1997) 1.56
MS: is it one disease? Int MS J (2009) 1.53
Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry (1984) 1.51
MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology (1999) 1.50
Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49
Diffusion-weighted imaging of patients with subacute cerebral ischemia: comparison with conventional and contrast-enhanced MR imaging. AJNR Am J Neuroradiol (2000) 1.49
A frame shift mutation in the PMP22 gene in hereditary neuropathy with liability to pressure palsies. Nat Genet (1994) 1.47
The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol (2001) 1.43
Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40
Dominance of autoreactive T cell-mediated delayed-type hypersensitivity or antibody-mediated demyelination results in distinct forms of experimental autoimmune neuritis in the Lewis rat. J Neuropathol Exp Neurol (2001) 1.39
[Physical trauma and multiple sclerosis]. Nervenarzt (1997) 1.38
Conduction block in vasculitic neuropathy. Muscle Nerve (1998) 1.38
Spinal root and plexus hypertrophy in chronic inflammatory demyelinating polyneuropathy. Brain (1999) 1.34
Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34
Peripheral neuropathy associated with mitochondrial myopathy. Ann Neurol (1986) 1.32
Platelet activating factor (PAF) induces the oxidative burst in macrophages. Int J Immunopharmacol (1983) 1.31
Molecular mechanisms of microglial activation. Adv Neuroimmunol (1996) 1.29
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. Mult Scler (2012) 1.24
Acute idiopathic polyneuritis. A clinical and electrophsiological follow-up study. J Neurol Sci (1976) 1.22
Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler (2011) 1.19
Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol (1995) 1.19
Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med (2000) 1.19
Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol (1999) 1.16
Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol (1983) 1.16
Human rabies encephalomyelitis. Br Med J (1976) 1.15
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology (2005) 1.14
Production and characterization of monoclonal antibodies to the extracellular domain of P0. J Neurosci Res (1993) 1.13
Recurrent experimental allergic neuritis. An electron microscope study. J Neurol Sci (1975) 1.13
Hypothyroid polyneuropathy. Clinical, electrophysiological and nerve biopsy findings in two cases. J Neurol Sci (1982) 1.12
Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler (2010) 1.11
Synthesis of complement by macrophages and modulation of their functions through complement activation. Springer Semin Immunopathol (1983) 1.10
HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis. Ann Neurol (1978) 1.10
Vasculitis confined to peripheral nerves. Brain (1996) 1.09
Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Int J Dev Neurosci (1995) 1.08
Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol (1986) 1.08
Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol (1999) 1.08
Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol (1992) 1.08
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 1.07
T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci (1997) 1.07
Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol (1993) 1.07
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain (1998) 1.07
Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med (Berl) (2005) 1.06
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 1.06
Chronic inflammatory demyelinating polyradiculoneuropathy associated with pregnancy. Ann Neurol (1987) 1.06
The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci (1999) 1.06
Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol (1997) 1.06
Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol (2009) 1.05
Blockade of chemokine signaling in patients with multiple sclerosis. Neurology (2006) 1.05
Frequency and location of microbleeds in patients with primary intracerebral hemorrhage. Stroke (2000) 1.05
Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci (2000) 1.05
Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother (2008) 1.04
A locus for hereditary sensory neuropathy with cough and gastroesophageal reflux on chromosome 3p22-p24. Am J Hum Genet (2003) 1.04
Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology (1999) 1.04
Quantitative studies of the secretion of complement component C3 by resident, elicited and activated macrophages. Comparison with C2, C4 and lysosomal enzyme release. Eur J Immunol (1982) 1.04
ADEM: distinct disease or part of the MS spectrum? Neurology (2001) 1.03
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part II. Muscle Nerve (1995) 1.03
Phenotype-genotype correlations in a CMT2B family with refined 3q13-q22 locus. Neurology (2000) 1.03
Ulcero-mutilating neuropathy in an Austrian kinship without linkage to hereditary motor and sensory neuropathy IIB and hereditary sensory neuropathy I loci. Neurology (2000) 1.02
Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain (2001) 1.02
Role of integrins in the peripheral nervous system. Prog Neurobiol (2001) 1.02
Differential expression of matrix metalloproteinases in bacterial meningitis. Brain (1999) 1.02
Induction of thromboxane release from macrophages by anaphylatoxic peptide C3a of complement and synthetic hexapeptide C3a 72-77. J Immunol (1983) 1.01
Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol (1993) 1.01
Clinical syndromes associated with tomacula or myelin swellings in sural nerve biopsies. J Neurol Neurosurg Psychiatry (2000) 1.01
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. Muscle Nerve (1995) 1.01
Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve (1998) 1.00
Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain (1999) 1.00
Peripheral facial palsy: etiology, diagnosis and treatment. Eur Neurol (1999) 1.00
Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol (1998) 0.99
Cloning, sequencing and molecular analysis of the Campylobacter jejuni groESL bicistronic operon. Microbiology (1999) 0.99
MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol (1996) 0.99
Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol (1992) 0.99
Relationship between stress and relapse in multiple sclerosis: Part II. Direct and indirect relationships. Mult Scler (2006) 0.98
The Bradykinesia Akinesia Incoordination Test (BRAIN TEST), an objective and user-friendly means to evaluate patients with parkinsonism. Mov Disord (2000) 0.98
Class II antigen expression and inflammatory cells in the Guillain-Barré syndrome. Ann Neurol (1987) 0.98
Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol (1999) 0.97